29 November 2021

ASX Announcement

RESULTS OF ANNUAL GENERAL MEETING

MELBOURNE Australia, 29 November 2021: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform advises that its Annual General Meeting was held today at 2:00pm AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary. All resolutions were carried with more than 99% of votes cast in favour of each.

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
November 2021

Notes to editor

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and properties of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. A second target implicated in fibrosis is in discovery research.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a revenue generating agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development. It also has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies to bring new hope to patients with cancer.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au

Disclosure of Proxy Votes

AdAlta Limited

Annual General Meeting

Monday, 29 November 2021

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**
1 Adoption of Remuneration Report	P	121,036,070	120,830,196 99.83%	96,481 0.08%	25,000	109,393 0.09%	125,759,005 99.92%	96,481 0.08%	25,000
2 Re-election of Director – Ms Elizabeth (Liddy) McCall	P	121,498,244	120,075,781 98.83%	1,313,070 1.08%	47,101	109,393 0.09%	125,004,590 98.96%	1,313,070 1.04%	47,101
3 Re-election of Director – Dr Robert Peach	P	121,498,244	121,375,781 99.90%	13,070 0.01%	47,101	109,393 0.09%	126,304,590 99.99%	13,070 0.01%	47,101
4 Approval of issue of Options to Dr Timothy Oldham, Director of the Company	P	121,061,070	120,637,787 99.65%	319,752 0.26%	0	103,531 0.09%	125,560,734 99.75%	319,752 0.25%	0
5 Approval of issue of Options to Dr Paul MacLeman, Director of the Company	P	121,061,070	120,037,755 99.15%	919,784 0.76%	106,607	103,531 0.09%	124,960,702 99.27%	919,784 0.73%	106,607
6 Approval of issue of Options to Dr Robert Peach, Director of the Company	P	119,761,070	119,337,787 99.65%	319,752 0.27%	1,300,000	103,531 0.09%	124,260,734 99.74%	319,752 0.26%	1,300,000
7 Approval of issue of Options to Dr David Fuller, Director of the Company	P	119,761,070	118,737,755 99.15%	919,784 0.77%	1,300,000	103,531 0.09%	123,660,702 99.26%	919,784 0.74%	1,300,000

			Proxy Votes				Poll Results (if applicable)		
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**
8 Approval of 10% placement capacity	P	121,545,345	121,183,282 99.70%	298,532 0.25%	0	63,531 0.05%	126,066,229 99.76%	298,532 0.24%	0
9 Adoption of New Constitution	P	121,445,345	121,249,583 99.84%	92,231 0.08%	100,000	103,531 0.09%	126,168,370 99.92%	96,391 0.08%	100,000

